Mediclarum
Medicine guide

Tranexamic Acid

10 mg/mL · Injection, Solution

  • Prescription only
  • Antifibrinolytic Agent
Active substance
Tranexamic Acid
Made by
Nexus Pharmaceuticals LLC

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

At a glance

Quoted from the official label · 2025-02-26

What it is

Antifibrinolytic Agent

Used for
  • Tranexamic Acid in Sodium Chloride Injection is indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during…
The label’s usual adult dose

Administer 10 mg/kg actual body weight of Tranexamic Acid in Sodium Chloride Injection intravenously with replacement therapy.

Full directions ↓
Do not take it if

Tranexamic Acid in Sodium Chloride Injection is contraindicated:

All warnings ↓
Good to know
  • Prescription only
  • FDA enforcement reports list no ongoing recall, and none from the last two years, for this product code · checked 2026-10-02
41other products contain Tranexamic Acid — compare makers, forms and strengths

Every line above is selected, not written, from the official label. Nothing is reworded. DailyMed

What it is for

  • Tranexamic Acid in Sodium Chloride Injection is indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.
  • Tranexamic Acid in Sodium Chloride Injection is an antifibrinolytic indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction ( 1 ).

From the official label · 2025-02-26 · DailyMed

How it works

From this product’s own US prescribing label.

Tranexamic acid is a synthetic lysine amino acid derivative, which diminishes the dissolution of hemostatic fibrin by plasmin.

In the presence of tranexamic acid, the lysine receptor binding sites of plasmin for fibrin are occupied, preventing binding to fibrin monomers, thus preserving and stabilizing fibrin's matrix structure.

Half-life2 h
Mostly cleared after≈ 10 hfive half-lives — our arithmetic
How it leaves the body

Overall renal clearance is equal to overall plasma clearance (110 to 116 mL/min), and more than 95% of the dose is excreted in the urine as unchanged drug.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-02-26

Do not take it if

  • Tranexamic Acid in Sodium Chloride Injection is contraindicated:
  • In patients with subarachnoid hemorrhage.
  • Anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by tranexamic acid in such patients.
  • In patients with active intravascular clotting [see Warnings and Precautions ( 5.1 )] .
  • In patients with hypersensitivity to tranexamic acid or any of the ingredients [see Warnings and Precautions ( 5.3 )] .
  • In patients with subarachnoid hemorrhage, due to risk of cerebral edema and cerebral infarction ( 4 ).
  • In patients with active intravascular clotting ( 4 ).
  • In patients with severe hypersensitivity reactions to tranexamic acid or any of the ingredients ( 4 ).

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

  • Before Extraction:
  • Administer 10 mg/kg actual body weight of Tranexamic Acid in Sodium Chloride Injection intravenously with replacement therapy.
  • After Extraction:
  • Administer 10 mg/kg actual body weight 3 to 4 times daily for 2 to 8 days.
  • Infuse no more than 10 mL/minute to avoid hypotension ( 2.1 ).
  • Reduce the dosage for patients with renal impairment ( 2.2 , 8.6 ).
  • 2.1 Recommended Dosage The recommended dose of Tranexamic Acid in Sodium Chloride Injection is 10 mg/kg actual body weight intravenously administered as a single dose, immediately before tooth extractions.
  • Infuse no more than 10 mL/minute to
  • avoid hypotension [see Warnings and Precautions ( 5.1 )] .
  • Following tooth extraction, Tranexamic Acid in Sodium Chloride Injection may be administered for 2 to 8 days at a dose of 10 mg/kg actual body weight three to four times daily, intravenously.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
  • Do not use Tranexamic Acid in Sodium Chloride Injection if particulate matter or coloration is seen.
  • Tranexamic Acid in Sodium Chloride Injection should NOT be mixed with blood.
  • The drug is a synthetic amino acid and should NOT be mixed with solutions containing penicillin.
  • The premix flexible plastic container bag contains no preservative; discard any unused portion.
  • 2.2 Recommended Dosage for Patients with Varying Degrees of Renal Impairment* For patients with moderate to severe impaired renal function, the following dosages are recommended:
  • Table 1.
  • Recommended Dosage in Patients with Varying Degrees of Renal Impairment *Dose reduction is recommended for all doses, both before and after tooth extraction.
  • Serum Creatinine (mg/dL) Tranexamic Acid in Sodium Chloride Injection Intravenous Dosage 1.36 to 2.83 (120 to 250 micromol/L) 10 mg/kg twice daily 2.83 to 5.66 (250 to 500 micromol/L) 10 mg/kg daily >5.66 (>500 micromol/L) 10 mg/kg every 48 hours or 5 mg/kg every 24 hours

Quoted from the official label, section “Dosage & Administration”.

Other warnings

  • Risk of Thrombosis with concomitant use of Factor IX: Avoid concomitant use ( 5.1 ).
  • Seizures: Inadvertent injection into neuraxial system may result in seizures ( 5.2 ).
  • Hypersensitivity Reactions:
  • In case of severe reaction, discontinue use and seek immediate medical attention ( 5.3 ).
  • Visual Disturbances: Visual or ocular adverse effects may occur.
  • Discontinue use if visual or ocular symptoms occur ( 5.4 ).
  • Dizziness.
  • Advise patients not to drive if dizziness occurs ( 5.5 ).
  • 5.1 Thromboembolic Risk Tranexamic Acid in Sodium Chloride Injection is contraindicated in patients with active intravascular clotting.
  • Tranexamic acid is an antifibrinolytic and may increase the risk of thromboembolic events.
  • Venous and arterial thrombosis or thromboembolism has been reported in patients treated with tranexamic acid.
  • Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection and medical products that are pro-thrombotic, as the risk of thrombosis may be increased.
  • These medications include but are not limited to, Factor IX Complex concentrates, Anti-inhibitor Coagulant concentrates, and hormonal contraceptives [see Drug Interactions ( 7.1 ), Use in Specific Populations ( 8.3 )] .
  • 5.2 Seizures Tranexamic acid may cause seizures, including focal and generalized seizures.
  • The most common setting for tranexamic acid-induced seizures has been during cardiovascular surgery (a setting in which Tranexamic Acid in Sodium Chloride Injection is not FDA approved and which uses doses of up to ten-fold higher than the recommended human dose and in patients inadvertently given tranexamic acid into the neuraxial system).
  • Tranexamic Acid in Sodium Chloride Injection is not approved and not recommended for neuraxial administration.
  • Consider dose reduction during surgery and dose adjustments for patients with clinical conditions such as renal dysfunction.
  • Closely monitor the patient during surgery.
  • Consider electroencephalogram (EEG) monitoring for patients with history of seizures or who experience myoclonic movements, twitching, or show evidence of focal seizures.
  • Discontinue Tranexamic Acid in Sodium Chloride Injection if seizures occur.
  • 5.3 Hypersensitivity Reactions Cases of hypersensitivity reactions, including anaphylactic reactions, have occurred with use of intravenous tranexamic acid.
  • Discontinue treatment with Tranexamic Acid in Sodium Chloride Injection if serious reaction occurs, provide appropriate medical management, and do not restart treatment.
  • Tranexamic Acid in Sodium Chloride Injection is contraindicated in patients with a history of hypersensitivity to tranexamic acid.
  • 5.4 Visual Disturbances Although not seen in humans, focal areas of retinal degeneration have been observed in cats and dogs following oral or intravenous tranexamic acid at doses between 250 to 1600 mg/kg/day (1.6 to 22 times the recommended usual human dose based on body surface area) from 6 days to 1 year.
  • No retinal changes have been observed in eye examinations of patients treated with tranexamic acid for up to 8 years.
  • Patients expected to be treated for greater than 3 months may consider ophthalmic monitoring including visual acuity and optical coherence tomography at regular intervals.
  • Discontinue Tranexamic Acid in Sodium Chloride Injection if changes in ophthalmological examination occurs.
  • 5.5 Dizziness Tranexamic acid may cause dizziness.
  • Concomitant use of other drugs that may also cause dizziness may worsen this effect.
  • Advise patients to
  • avoid driving or using machines until they know how Tranexamic Acid in Sodium Chloride Injection affects them.

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

  • Risk Summary Available data from published studies, case series and case reports with tranexamic acid use in pregnant women in the second and third trimester and at the time of delivery have not clarified whether there is a drug-associated risk of miscarriage or adverse maternal or fetal outcomes.
  • There are 2 (0.02%) infant cases with structural abnormalities that resulted in death when tranexamic acid was used during conception or the first trimester of pregnancy; however, due to other confounding factors the risk of major birth defects with use of tranexamic acid during pregnancy is not clear.
  • Tranexamic acid is known to pass the placenta and appears in cord blood at concentrations approximately equal to maternal concentration ( see Data ).
  • Reproduction studies performed in mice, rats, and rabbits have not revealed any adverse effects on the fetus due to tranexamic acid administered during organogenesis.
  • Doses examined were multiples of up to 3 times (mouse), 6 times (rat), and 3 times (rabbit) the maximum human dose based on body surface area in the mouse, rat, and rabbit, respectively (see Data ) .
  • The estimated background risk for major birth defects and miscarriage for the indicated population is unknown.
  • All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
  • In the U.S. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2-4% and 15-20%, respectively.
  • It is not known whether tranexamic acid use in pregnant women may cause a drug-associated risk of miscarriage or adverse maternal or fetal outcomes.
  • For decisions regarding the use of Tranexamic Acid in Sodium Chloride Injection during pregnancy, the potential risk of Tranexamic Acid in Sodium Chloride Injection administration on the fetus should always be considered along with the mother's clinical need for Tranexamic Acid in Sodium Chloride Injection; an accurate risk-benefit evaluation should drive the treating physician's decision.
  • Data Human Data Tranexamic acid passes through the placenta.
  • The concentration in cord blood after an intravenous injection of 10 mg/kg to pregnant women is about 30 mg/L, as high as in the maternal blood.
  • There were 13 clinical studies that described fetal and/or neonatal functional issues such as low Apgar score, neonatal sepsis, cephalohematoma and 9 clinical studies that discussed alterations to growth including low birth weight and preterm birth at 22-36 weeks of gestation in fetuses and infants exposed to tranexamic acid in-utero.
  • Animal Data In embryo-fetal development studies, tranexamic acid was administered to pregnant mice from Gestation day (GD) 6 through GD 12 and rats from GD 9 through GD 14 at daily doses of 0.3 or 1.5 g/kg.
  • There was no evidence of adverse developmental outcomes in mice and rats at multiple of 3 and 6 times the maximum recommended human dose based on body surface area in the mouse and rat, respectively.
  • In rabbits, tranexamic acid was administered intravenously at doses of 50, 100, or 200 mg/kg/day or orally at doses of 100, 200, or 400 mg/kg/day from GD 6 through GD 18.
  • There was no evidence of adverse developmental outcomes at dose multiples of 2 or 3 times, respectively, the maximum recommended human dose based on body surface area.
  • Intravenous doses of 200 mg/kg/day showed slightly retarded weight gain in pregnant rabbits.
  • IN SPECIFIC POPULATIONS
  • 8.1 Pregnancy Risk Summary Available data from published studies, case series and case reports with tranexamic acid use in pregnant women in the second and third trimester and at the time of delivery have not clarified whether there is a drug-associated risk of miscarriage or adverse maternal or fetal outcomes.
  • There are 2 (0.02%) infant cases with structural abnormalities that resulted in death when tranexamic acid was used during conception or the first trimester of pregnancy; however, due to other confounding factors the risk of major birth defects with use of tranexamic acid during pregnancy is not clear.
  • Tranexamic acid is known to pass the placenta and appears in cord blood at concentrations approximately equal to maternal concentration ( see Data ).
  • Reproduction studies performed in mice, rats, and rabbits have not revealed any adverse effects on the fetus due to tranexamic acid administered during organogenesis.
  • Doses examined were multiples of up to 3 times (mouse), 6 times (rat), and 3 times (rabbit) the maximum human dose based on body surface area in the mouse, rat, and rabbit, respectively (see Data ) .
  • The estimated background risk for major birth defects and miscarriage for the indicated population is unknown.
  • All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
  • In the U.S. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2-4% and 15-20%, respectively.
  • It is not known whether tranexamic acid use in pregnant women may cause a drug-associated risk of miscarriage or adverse maternal or fetal outcomes.
  • For decisions regarding the use of Tranexamic Acid in Sodium Chloride Injection during pregnancy, the potential risk of Tranexamic Acid in Sodium Chloride Injection administration on the fetus should always be considered along with the mother's clinical need for Tranexamic Acid in Sodium Chloride Injection; an accurate risk-benefit evaluation should drive the treating physician's decision.
  • Data Human Data Tranexamic acid passes through the placenta.
  • The concentration in cord blood after an intravenous injection of 10 mg/kg to pregnant women is about 30 mg/L, as high as in the maternal blood.
  • There were 13 clinical studies that described fetal and/or neonatal functional issues such as low Apgar score, neonatal sepsis, cephalohematoma and 9 clinical studies that discussed alterations to growth including low birth weight and preterm birth at 22-36 weeks of gestation in fetuses and infants exposed to tranexamic acid in-utero.
  • Animal Data In embryo-fetal development studies, tranexamic acid was administered to pregnant mice from Gestation day (GD) 6 through GD 12 and rats from GD 9 through GD 14 at daily doses of 0.3 or 1.5 g/kg.
  • There was no evidence of adverse developmental outcomes in mice and rats at multiple of 3 and 6 times the maximum recommended human dose based on body surface area in the mouse and rat, respectively.
  • In rabbits, tranexamic acid was administered intravenously at doses of 50, 100, or 200 mg/kg/day or orally at doses of 100, 200, or 400 mg/kg/day from GD 6 through GD 18.
  • There was no evidence of adverse developmental outcomes at dose multiples of 2 or 3 times, respectively, the maximum recommended human dose based on body surface area.
  • Intravenous doses of 200 mg/kg/day showed slightly retarded weight gain in pregnant rabbits.
  • 8.2 Lactation Risk Summary Published literature reports the presence of tranexamic acid in human milk.
  • There are no data on the effects of tranexamic acid on the breastfed child or the effects on milk production.
  • The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Tranexamic Acid in Sodium Chloride Injection and any potential adverse effects on the breastfed child from Tranexamic Acid in Sodium Chloride Injection or from the underlying maternal condition.
  • 8.3 Females and Males of Reproductive Potential Contraception Concomitant use of Tranexamic Acid in Sodium Chloride Injection, which is an antifibrinolytic, with hormonal contraceptives may increase the risk for thromboembolic adverse reactions.
  • Advise patients to use an effective alternative (nonhormonal) contraceptive method [see Warnings and Precautions ( 5.5 ), Drug Interactions ( 7.1 )] .
  • 8.4 Pediatric Use There are limited data concerning the use of tranexamic acid in pediatric patients with hemophilia who are undergoing tooth extraction.
  • The limited data suggest that there are no significant pharmacokinetic differences between adult and pediatric patients.
  • 8.5 Geriatric Use Clinical studies of tranexamic acid did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
  • Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
  • This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.
  • Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [Dosage and Administration ( 2.2 ), Clinical Pharmacology ( 12.3 )] .
  • 8.6 Renal Impairment Reduce the dosage of Tranexamic Acid in Sodium Chloride Injection in patients with renal impairment, based on the patient's serum creatinine [see Dosage and Administration ( 2.2 ), Clinical Pharmacology ( 12.3 )].

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

Other medicines

  • Prothrombotic Medical Products:
  • Avoid concomitant use, can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid ( 5.1 , 7.1 , 8.3 ).
  • Prothrombotic Medical Products
  • Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions ( 5.1 ), Use in Specific Populations ( 8.3 )].

Quoted from the official label, section “Drug Interactions”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

  • Cases of overdosage of tranexamic acid have been reported.
  • Based on these reports, symptoms of overdosage may be gastrointestinal, e.g., nausea, vomiting, diarrhea; hypotensive, e.g., orthostatic symptoms; thromboembolic; e.g., arterial, venous, embolic; neurologic, e.g., visual impairment, convulsions, headache, mental status changes; myoclonus; and rash.
  • Tranexamic acid is not dialyzable.

Quoted from the official label, section “Overdosage”.

Use in children

There are limited data concerning the use of tranexamic acid in pediatric patients with hemophilia who are undergoing tooth extraction. The limited data suggest that there are no significant pharmacokinetic differences between adult and pediatric patients.

Quoted from the official label, section “Pediatric Use”.

Use in older people

  • Clinical studies of tranexamic acid did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
  • Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
  • This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.
  • Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [Dosage and Administration ( 2.2 ), Clinical Pharmacology ( 12.3 )] .

Quoted from the official label, section “Geriatric Use”.

Side effects

  • The following clinically significant adverse reactions are described elsewhere in the labeling:
  • Thromboembolic Risk [see Warnings and Precautions ( 5.1 )] Seizures [see Warnings and Precautions ( 5.2 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.3 )] Visual Disturbances [see Warnings and Precautions ( 5.4 )] Dizziness [see Warnings and Precautions ( 5.5 )] Most common adverse reactions are nausea, vomiting, diarrhea, allergic dermatitis, giddiness, hypotension, and thromboembolic events ( 6 ).
  • To report SUSPECTED ADVERSE REACTIONS, contact Nexus Pharmaceuticals at (855) 642-2594 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
  • 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of tranexamic acid.
  • Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
  • Gastrointestinal disturbances (nausea, vomiting, diarrhea) may occur and may resolve with dose-reduction.
  • Allergic dermatitis and giddiness have been reported.
  • Hypotension has been reported when intravenous injection is too rapid.
  • Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, cerebral thrombosis, acute renal cortical necrosis, and central retinal artery, vein obstruction and cases associated with concomitant use of combination hormonal contraceptives) have been rarely reported in patients receiving tranexamic acid for indications other than hemorrhage prevention in patients with hemophilia.
  • Convulsion, cromatopsia, and visual impairment have also been reported.
  • Anaphylaxis or anaphylactoid reactions have been reported that are suggestive of a causal relationship.

Quoted from the official label, section “Adverse Reactions”.

What to discuss with your doctor

  • Thromboembolic Risk Inform patients that Tranexamic Acid in Sodium Chloride Injection may increase the risk of venous and arterial thrombosis or thromboembolism and to contact their healthcare provider for any signs or symptoms suggestive of thromboembolism.
  • Advise patients using hormonal contraception that combined use with Tranexamic Acid in Sodium Chloride Injection may increase the risk for thromboembolic adverse reactions and to use effective alternative (nonhormonal) contraception during therapy with Tranexamic Acid in Sodium Chloride Injection [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7.1 ), Use in Specific Populations ( 8.3 )] .
  • Seizures Inform patients that Tranexamic Acid in Sodium Chloride Injection may cause seizures and to contact their healthcare provider for any signs or symptoms suggestive of seizures [see Warnings and Precautions ( 5.2 )].
  • Hypersensitivity Reactions Inform patients that Tranexamic Acid in Sodium Chloride Injection may cause hypersensitivity reactions and to contact their healthcare provider for any signs or symptoms of hypersensitivity reactions [see Warnings and Precautions ( 5.3 )].
  • Visual Disturbances Inform patients that Tranexamic Acid in Sodium Chloride Injection can cause visual disturbance and that they should report any eye symptoms or change in their vision to their healthcare provider and to follow-up with an ophthalmologist for a complete ophthalmologic evaluation, including dilated retinal examination of the retina [see Warnings and Precautions ( 5.4 )] .
  • Risk of Driving and Operating Machinery Inform patients that Tranexamic Acid in Sodium Chloride Injection may cause dizziness, and that the patient should be cautioned about driving, operating machinery, or performing hazardous tasks while taking Tranexamic Acid in Sodium Chloride Injection [see Warnings and Precautions ( 5.5 )] .
  • Manufactured in UK for:
  • Nexus Pharmaceuticals, LLC 400 Knightsbridge Parkway Lincolnshire, IL 60069 USA TRAPI01GBR01 Logo

Quoted from the official label, section “Patient Counseling Information”.

Strengths and forms

  • FORMS AND STRENGTHS Injection:
  • 1,000 mg of tranexamic acid in 100 mL (10 mg/mL), colorless solution in a single-dose bag for intravenous use Injection:
  • 1,000 mg of tranexamic acid in 100 mL (10 mg/mL) sterile, unpreserved, colorless solution in a single-dose bag for intravenous use ( 3 ).

Quoted from the official label, section “Dosage Forms & Strengths”.

What it looks like and how it is packed

  • Tranexamic Acid in Sodium Chloride Injection is supplied as a sterile, unpreserved, colorless solution in a single-dose polymeric bag containing 1000 mg tranexamic acid in 100 mL of solution (10 mg/mL) sealed with a Twist Off port and oversealed in an aluminum pouch as follows:
  • Strength Package NDC Number 1000 mg (10 mg/mL) 1 single-dose bag 14789-115-08 10 bags per carton 14789-115-05 Discard any unused portion.
  • Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

Quoted from the official label, section “How Supplied”.

What is in it

  • Tranexamic acid is trans-4-(aminomethyl)cyclohexanecarboxylic acid, an antifibrinolytic agent.
  • Tranexamic acid is a white crystalline powder.
  • The structural formula is Empirical Formula: C 8 H 15 NO 2 Molecular Weight:
  • 157.2 Tranexamic Acid in Sodium Chloride Injection is a clear to colorless sterile, nonpyrogenic injectable solution for intravenous administration.
  • Each IV bag contains 1,000 mg tranexamic acid, USP, 700 mg of sodium chloride, USP and Water for Injection, USP.
  • The aqueous solution has a pH of 6.5 to 8.0.
  • Structural Formula

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

The stored label for this product has no list of inactive ingredients. The list on the pack is the one to check.

Quoted from the FDA label. A label that does not name an ingredient is not a guarantee that the product is free of it, and formulations change. With an allergy, check the pack and ask a pharmacist.

Every version of this medicine (8)

The same active substance, strength and kind of form, from every company that sells it — with what each label lists.

Showing 8 of 8

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

CanadaNo exact match for this strength and form

Every strength and form (21)

Details

Made byNexus Pharmaceuticals LLC
Active substanceTranexamic Acid
Used inBlood, clotting and anaemia
Strength10 mg/mL
FormInjection, Solution
RouteIntravenous
Packs10 BAG in 1 CARTON / 100 mL in 1 BAG
NDC14789-115

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Other strengths and forms

35 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

Cyklokapron100 mg/mLPrescription onlyInjection, Solution Pfizer Laboratories Div Pfizer Inc · Tranexamic AcidTranexamic Acid650 mgPrescription onlyTablet, Film Coated Actavis Pharma, Inc. · Tranexamic AcidTranexamic Acid1 g/10mLPrescription onlyInjection, Solution Emcure Pharmaceuticals Limited · Tranexamic AcidTranexamic Acid1 g/10mLPrescription onlyInjection, Solution Heritage Pharmaceuticals Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. · Tranexamic AcidTranexamic Acid100 mg/mLPrescription onlyInjection Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. · Tranexamic AcidTranexamic Acid100 mg/mLPrescription onlyInjection, Solution Sagent Pharmaceuticals · Tranexamic Acid

See every product with Tranexamic Acid